Legnano, Italy

Olga Valota

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Nerviano Medical Sciences S.r.l.. Active years: 2015.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Olga Valota - Innovator in Pharmaceutical Composition

Introduction

Olga Valota is a distinguished inventor based in Legnano, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions for cancer treatment. Her work is characterized by a commitment to improving therapeutic options for patients.

Latest Patents

Olga Valota holds 1 patent for her invention titled "Pharmaceutical composition of an anthracycline." This patent relates to a pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are particularly useful for chemoembolization, especially for loco-regional treatment of tumors.

Career Highlights

Olga Valota is currently associated with Nerviano Medical Sciences S.r.l., where she continues to advance her research and development efforts. Her work has been instrumental in enhancing the efficacy of cancer treatments through innovative pharmaceutical formulations.

Collaborations

Throughout her career, Olga has collaborated with notable colleagues, including Maria Cristina Geroni and Alessandro Martini. These partnerships have fostered a collaborative environment that promotes the exchange of ideas and expertise in the pharmaceutical field.

Conclusion

Olga Valota's contributions to pharmaceutical innovation exemplify her dedication to improving cancer treatment options. Her work not only highlights her inventive spirit but also underscores the importance of collaboration in advancing medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…